Show simple item record

dc.creatorLaustsen, Andreas Hougaard
dc.creatorGutiérrez, José María
dc.creatorKnudsen, Cecilie
dc.creatorJohansen, Kristoffer H.
dc.creatorBermúdez Méndez, Erick
dc.creatorCerni, Felipe A.
dc.creatorJürgensen, Jonas A.
dc.creatorLedsgaard, Line
dc.creatorMartos Esteban, Andrea
dc.creatorØhlenschlæger, Mia
dc.creatorPus, Urska
dc.creatorAndersen, Mikael Rørdam
dc.creatorLomonte, Bruno
dc.creatorEngmark, Mikael Gerling
dc.creatorPucca, Manuela Berto
dc.date.accessioned2019-02-04T16:29:56Z
dc.date.available2019-02-04T16:29:56Z
dc.date.issued2018-05
dc.identifier.citationhttps://www.sciencedirect.com/science/article/pii/S0041010118301144?via%3Dihubes_ES
dc.identifier.issn0041-0101
dc.identifier.urihttp://hdl.handle.net/10669/76544
dc.description.abstractAntibody technologies are being increasingly applied in the field of toxinology. Fuelled by the many advances in immunology, synthetic biology, and antibody research, different approaches and antibody formats are being investigated for the ability to neutralize animal toxins. These different molecular formats each have their own therapeutic characteristics. In this review, we provide an overview of the advances made in the development of toxin-targeting antibodies, and discuss the benefits and drawbacks of different antibody formats in relation to their ability to neutralize toxins, pharmacokinetic features, propensity to cause adverse reactions, formulation, and expression for research and development (R&D) purposes and large-scale manufacturing. A research trend seems to be emerging towards the use of human antibody formats as well as camelid heavy-domain antibody fragments due to their compatibility with the human immune system, beneficial therapeutic properties, and the ability to manufacture these molecules cost-effectively.es_ES
dc.description.sponsorshipNovo Nordisk Foundation/[16OC0019248]/NNF/Dinamarcaes_ES
dc.description.sponsorshipNovo Nordisk Foundation/[13OC0005613]/NNF/Dinamarcaes_ES
dc.description.sponsorshipMinisterio de Ciencia, Tecnología y Telecomunicaciones/[PEM-066-2015-II]/MICITT/Costa Ricaes_ES
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnologico/[150749/2017-1]/CNPq/Brasiles_ES
dc.description.sponsorshipUniversidad de Costa Rica/[OAICE-CAB-05-56-2016]/UCR/Costa Ricaes_ES
dc.language.isoen_USes_ES
dc.sourceToxicon, vol.146, pp. 151-175.es_ES
dc.subjectAntivenomes_ES
dc.subjectVenomes_ES
dc.subjectRecombinant antivenomes_ES
dc.subjectAntibodieses_ES
dc.subjectSnakebitees_ES
dc.subjectScorpion stinges_ES
dc.subjectSpider bitees_ES
dc.subjectAnimal envenominges_ES
dc.subjectPharmacokineticses_ES
dc.subjectPharmacodynamicses_ES
dc.subjectImmunogenicityes_ES
dc.subjectVenom neutralizationes_ES
dc.subjectAntibody expressiones_ES
dc.subjectAntivenom designes_ES
dc.subjectAdverse reactionses_ES
dc.subjectNeglected tropical diseaseses_ES
dc.subjectBiotechnologyes_ES
dc.subject615.946 Venenos animaleses_ES
dc.titlePros and cons of different therapeutic antibody formats for recombinant antivenom developmentes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.identifier.doi10.1016/j.toxicon.2018.03.004
dc.description.procedenceUCR::Vicerrectoría de Investigación::Unidades de Investigación::Ciencias de la Salud::Instituto Clodomiro Picado (ICP)es_ES
dc.description.procedenceUCR::Vicerrectoría de Docencia::Salud::Facultad de Microbiologíaes_ES


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record